IFITM2 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
natural killer cell	46 studies	78% ± 21%	Explore
endothelial cell	41 studies	70% ± 22%	Explore
fibroblast	41 studies	58% ± 20%	Explore
CD8-positive, alpha-beta T cell	39 studies	57% ± 21%	Explore
B cell	38 studies	44% ± 17%	Explore
T cell	35 studies	51% ± 19%	Explore
pericyte	34 studies	64% ± 21%	Explore
CD4-positive, alpha-beta T cell	34 studies	59% ± 19%	Explore
macrophage	31 studies	42% ± 16%	Explore
conventional dendritic cell	29 studies	54% ± 21%	Explore
regulatory T cell	27 studies	54% ± 14%	Explore
classical monocyte	26 studies	66% ± 17%	Explore
smooth muscle cell	24 studies	57% ± 21%	Explore
non-classical monocyte	24 studies	88% ± 17%	Explore
monocyte	23 studies	63% ± 20%	Explore
endothelial cell of lymphatic vessel	23 studies	73% ± 18%	Explore
mast cell	22 studies	57% ± 19%	Explore
mature NK T cell	22 studies	74% ± 17%	Explore
dendritic cell	21 studies	53% ± 23%	Explore
memory B cell	20 studies	53% ± 13%	Explore
naive B cell	20 studies	48% ± 16%	Explore
connective tissue cell	20 studies	58% ± 16%	Explore
gamma-delta T cell	19 studies	68% ± 15%	Explore
plasmacytoid dendritic cell	19 studies	40% ± 20%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	18 studies	53% ± 17%	Explore
neutrophil	18 studies	80% ± 20%	Explore
basal cell	17 studies	33% ± 21%	Explore
CD16-negative, CD56-bright natural killer cell, human	16 studies	86% ± 17%	Explore
mucosal invariant T cell	16 studies	64% ± 18%	Explore
CD16-positive, CD56-dim natural killer cell, human	15 studies	87% ± 13%	Explore
endothelial cell of artery	15 studies	76% ± 21%	Explore
capillary endothelial cell	15 studies	75% ± 15%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	14 studies	63% ± 20%	Explore
vein endothelial cell	14 studies	71% ± 23%	Explore
endothelial cell of vascular tree	14 studies	71% ± 24%	Explore
myeloid cell	14 studies	43% ± 12%	Explore
epithelial cell	13 studies	33% ± 17%	Explore
myofibroblast cell	13 studies	55% ± 21%	Explore
effector memory CD8-positive, alpha-beta T cell	12 studies	59% ± 19%	Explore
CD4-positive, alpha-beta memory T cell	12 studies	60% ± 18%	Explore
CD8-positive, alpha-beta memory T cell	12 studies	62% ± 19%	Explore
innate lymphoid cell	11 studies	74% ± 21%	Explore
mesothelial cell	11 studies	60% ± 24%	Explore
ciliated cell	10 studies	38% ± 16%	Explore
type II pneumocyte	9 studies	53% ± 20%	Explore
type I pneumocyte	8 studies	45% ± 13%	Explore
leukocyte	8 studies	42% ± 12%	Explore
hematopoietic stem cell	8 studies	60% ± 21%	Explore
T follicular helper cell	8 studies	55% ± 15%	Explore
secretory cell	7 studies	58% ± 27%	Explore
platelet	7 studies	52% ± 17%	Explore
effector CD8-positive, alpha-beta T cell	7 studies	68% ± 18%	Explore
abnormal cell	7 studies	38% ± 22%	Explore
CD4-positive helper T cell	6 studies	55% ± 14%	Explore
effector CD4-positive, alpha-beta T cell	6 studies	71% ± 21%	Explore
mononuclear phagocyte	6 studies	41% ± 20%	Explore
kidney loop of Henle epithelial cell	6 studies	36% ± 16%	Explore
plasma cell	6 studies	36% ± 18%	Explore
intermediate monocyte	6 studies	69% ± 26%	Explore
effector memory CD4-positive, alpha-beta T cell	6 studies	68% ± 13%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	5 studies	75% ± 13%	Explore
hematopoietic precursor cell	5 studies	55% ± 6%	Explore
exhausted T cell	5 studies	66% ± 17%	Explore
plasmablast	5 studies	47% ± 19%	Explore
precursor B cell	5 studies	54% ± 14%	Explore
club cell	5 studies	46% ± 24%	Explore
T-helper 17 cell	5 studies	71% ± 15%	Explore
immature B cell	5 studies	67% ± 8%	Explore
granulocyte	5 studies	58% ± 23%	Explore
CD4-positive, alpha-beta cytotoxic T cell	4 studies	58% ± 25%	Explore
central memory CD8-positive, alpha-beta T cell	4 studies	62% ± 14%	Explore
endothelial cell of sinusoid	4 studies	43% ± 21%	Explore
glomerular endothelial cell	4 studies	84% ± 7%	Explore
kidney distal convoluted tubule epithelial cell	4 studies	36% ± 9%	Explore
astrocyte	4 studies	21% ± 5%	Explore
lymphocyte	4 studies	75% ± 12%	Explore
pro-B cell	4 studies	48% ± 8%	Explore
adventitial cell	4 studies	81% ± 12%	Explore
luminal hormone-sensing cell of mammary gland	4 studies	42% ± 16%	Explore
glial cell	4 studies	33% ± 11%	Explore
group 3 innate lymphoid cell	4 studies	65% ± 12%	Explore
double negative thymocyte	4 studies	59% ± 21%	Explore
erythrocyte	4 studies	43% ± 16%	Explore
respiratory goblet cell	3 studies	45% ± 20%	Explore
monocyte-derived dendritic cell	3 studies	51% ± 28%	Explore
podocyte	3 studies	42% ± 8%	Explore
progenitor cell	3 studies	46% ± 20%	Explore
renal alpha-intercalated cell	3 studies	39% ± 19%	Explore
neural crest cell	3 studies	26% ± 2%	Explore
thymocyte	3 studies	33% ± 7%	Explore
erythroblast	3 studies	21% ± 3%	Explore
megakaryocyte	3 studies	53% ± 10%	Explore
microglial cell	3 studies	37% ± 11%	Explore
intraepithelial lymphocyte	3 studies	56% ± 9%	Explore
germinal center B cell	3 studies	23% ± 1%	Explore
myoepithelial cell	3 studies	46% ± 17%	Explore
pancreatic ductal cell	3 studies	62% ± 19%	Explore
megakaryocyte-erythroid progenitor cell	3 studies	68% ± 29%	Explore
hepatocyte	3 studies	38% ± 14%	Explore
T-helper 1 cell	3 studies	78% ± 7%	Explore
central memory CD4-positive, alpha-beta T cell	3 studies	74% ± 9%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	20 studies	65% ± 16%	Explore
lung	18 studies	45% ± 15%	Explore
kidney	9 studies	39% ± 15%	Explore
intestine	8 studies	36% ± 8%	Explore
liver	6 studies	40% ± 15%	Explore
bone marrow	5 studies	49% ± 19%	Explore
lymph node	5 studies	44% ± 17%	Explore
uterus	5 studies	65% ± 18%	Explore
heart	4 studies	27% ± 6%	Explore
prostate	4 studies	28% ± 5%	Explore
skin	4 studies	35% ± 12%	Explore
breast	4 studies	45% ± 6%	Explore
adrenal gland	3 studies	39% ± 19%	Explore
pancreas	3 studies	20% ± 4%	Explore
placenta	3 studies	30% ± 12%	Explore
thymus	3 studies	33% ± 10%	Explore
brain	3 studies	37% ± 7%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
ovary	100%	14255.98	180 / 180	100%	466.25	428 / 430
liver	98%	15839.69	222 / 226	97%	327.83	395 / 406
breast	100%	15406.93	459 / 459	95%	252.87	1065 / 1118
lung	100%	24113.87	577 / 578	94%	210.48	1087 / 1155
thymus	100%	10696.08	650 / 653	89%	101.88	538 / 605
uterus	100%	16882.87	170 / 170	88%	213.47	406 / 459
prostate	96%	9649.72	234 / 245	92%	120.89	462 / 502
kidney	100%	13629.22	89 / 89	87%	242.99	788 / 901
intestine	86%	6928.53	827 / 966	96%	259.32	506 / 527
bladder	95%	11195.90	20 / 21	77%	158.36	388 / 504
esophagus	88%	7797.40	1272 / 1445	84%	145.68	154 / 183
skin	78%	8555.97	1417 / 1809	89%	234.65	421 / 472
adrenal gland	94%	6450.09	242 / 258	63%	85.97	145 / 230
stomach	60%	5069.89	215 / 359	96%	262.12	275 / 286
pancreas	29%	1525.80	96 / 328	94%	306.90	168 / 178
lymph node	0%	0	0 / 0	100%	283.78	29 / 29
spleen	100%	31556.93	241 / 241	0%	0	0 / 0
adipose	100%	19152.51	1203 / 1204	0%	0	0 / 0
peripheral blood	99%	178033.88	920 / 929	0%	0	0 / 0
blood vessel	98%	14595.43	1302 / 1335	0%	0	0 / 0
eye	0%	0	0 / 0	98%	284.96	78 / 80
heart	96%	8442.45	825 / 861	0%	0	0 / 0
tonsil	0%	0	0 / 0	87%	83.88	39 / 45
brain	24%	1264.65	643 / 2642	55%	63.45	385 / 705
muscle	28%	1323.06	222 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0009615	Biological process	response to virus
GO_0006955	Biological process	immune response
GO_0051607	Biological process	defense response to virus
GO_0060337	Biological process	type I interferon-mediated signaling pathway
GO_0035455	Biological process	response to interferon-alpha
GO_0045071	Biological process	negative regulation of viral genome replication
GO_0046597	Biological process	negative regulation of viral entry into host cell
GO_0034341	Biological process	response to type II interferon
GO_0035456	Biological process	response to interferon-beta
GO_0035458	Biological process	cellular response to interferon-beta
GO_0032991	Cellular component	protein-containing complex
GO_0031902	Cellular component	late endosome membrane
GO_0005886	Cellular component	plasma membrane
GO_0005765	Cellular component	lysosomal membrane

IV. Literature review

[source]

Gene name	IFITM2
Protein name	Interferon induced transmembrane protein 2 Interferon-induced transmembrane protein 2 (Dispanin subfamily A member 2c) (DSPA2c) (Interferon-inducible protein 1-8D) IFITM2 protein (Interferon induced transmembrane protein 2 (1-8D))
Synonyms
Description	FUNCTION: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol . Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) . Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry . Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation . IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome . .
Accessions	A0A7P0TB81 ENST00000680261.1 ENST00000533141.1 Q6IBB0 ENST00000681900.1 ENST00000399817.9 A0A7P0T9Q3 ENST00000602569.2 A0A7P0TA08 ENST00000527146.1 ENST00000680619.1 A0A7P0TAK5 ENST00000681810.1 ENST00000680081.1 H0YCL2 A0A804CKL3 ENST00000679962.1 ENST00000681211.1 Q01629 ENST00000681914.1 ENST00000681833.1 ENST00000681276.1 ENST00000680197.1 ENST00000616316.3 R4GNC9 E9PQN9 A0A7P0T953 A0A7P0T856 ENST00000680344.1

IFITM2 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review